Follow the people · Insider
Jason Aryeh
Jason Aryeh files insider transactions with the SEC as a director of Orchestra BioMed Holdings (OBIO). We hold 4 disclosed purchases and sales filed since 29 September 2006, 2 of them in the last 90 days.
- Files forOBIO
- Disclosed buys and sells4 in all, 2 in the last 90 days
- Last disclosure12 June 2026
Positions held
13 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 26 January 2023 — 23 June 2026Director · Orchestra BioMed Holdings (OBIO)20 Form 4 lines · source: SEC Form 4
- Filed 27 September 2006 — 11 June 2026Director · Ligand Pharmaceuticals (LGND)150 Form 4 lines · source: SEC Form 4
- Filed 19 August 2024 — 4 June 2026Director · Lifecore Biomedical, Inc. \de\ (LFCR)3 Form 4 lines · source: SEC Form 4
- Filed 21 April 2022 — 4 April 2025Director · Anebulo Pharmaceuticals (ANEB)5 Form 4 lines · source: SEC Form 4
- Filed 11 July 2019 — 16 July 2019TenPercentOwnerOther · Merrimack Pharmaceuticals (MACK)4 Form 4 lines · source: SEC Form 4
- Filed 16 June 2016 — 23 May 2017Director · Aralez Pharmaceuticals (ARLZ)8 Form 4 lines · source: SEC Form 4
- Filed 29 November 2016 — 15 May 2017Director · Qlt Inc/bc (NVLN)6 Form 4 lines · source: SEC Form 4
- Filed 8 January 2017 — 8 January 2017Director · Immunomedics (IMMU)1 Form 4 line · source: SEC Form 4
- Filed 10 July 2012 — 17 June 2016Director · Qlt Inc/bc (QLTI)36 Form 4 lines · source: SEC Form 4
- Filed 19 October 2011 — 18 June 2012Director · Myrexis (MYRX)58 Form 4 lines · source: SEC Form 4
- Filed 16 June 2012 — 16 June 2012Director · Qlt Inc/bc (QLT)4 Form 4 lines · source: SEC Form 4
- Filed 10 November 2011 — 10 November 2011Director · Ligand Pharmaceuticals (LGNDD)2 Form 4 lines · source: SEC Form 4
- Filed 10 November 2006 — 25 May 2011Director · Nabi Biopharmaceuticals (NABI)88 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- was granted 42,553 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 425 June 2026Stock Option (Right to Buy) · traded 23 June 2026 · filed 25 June 2026
- was granted 836 shares of Ligand PharmaceuticalsSEC Form 412 June 2026Common Stock · traded 5 June 2026 · filed 12 June 2026
- ▼ sold on the open market 500 shares of Ligand PharmaceuticalsSEC Form 412 June 2026Common Stock · traded 10 June 2026 · filed 12 June 2026
- ▼ sold on the open market 4,500 shares of Ligand PharmaceuticalsSEC Form 412 June 2026Common Stock · traded 11 June 2026 · filed 12 June 2026
- was granted 2,938 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 412 June 2026Non-Qualified Stock Option (right to buy) · traded 5 June 2026 · filed 12 June 2026
- was granted 25,907 shares of Lifecore Biomedical, Inc. \de\SEC Form 45 June 2026Common Stock · traded 4 June 2026 · filed 5 June 2026
- ▲ bought on the open market 665 shares of Orchestra BioMed HoldingsSEC Form 420 May 2026Common Stock, par value $0.0001 per share · traded 18 May 2026 · filed 20 May 2026
- ▲ bought on the open market 8,971 shares of Orchestra BioMed HoldingsSEC Form 419 May 2026Common Stock, par value $0.0001 per share · traded 15 May 2026 · filed 19 May 2026
- exercised options over 2,034 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 48 December 2025Non-Qualified Stock Option (right to buy) · traded 8 December 2025 · filed 8 December 2025
- exercised options over 2,034 shares of Ligand PharmaceuticalsSEC Form 48 December 2025Common Stock · traded 8 December 2025 · filed 8 December 2025
- ▼ sold on the open market 4,418 shares of Ligand PharmaceuticalsSEC Form 424 September 2025Common Stock · traded 23 September 2025 · filed 24 September 2025
- ▼ sold on the open market 4,628 shares of Ligand PharmaceuticalsSEC Form 424 September 2025Common Stock · traded 23 September 2025 · filed 24 September 2025
- ▼ sold on the open market 954 shares of Ligand PharmaceuticalsSEC Form 424 September 2025Common Stock · traded 23 September 2025 · filed 24 September 2025
- ▲ bought on the open market 1,000 shares of Orchestra BioMed HoldingsSEC Form 419 September 2025Common Stock, par value $0.0001 per share · traded 19 September 2025 · filed 19 September 2025
- was granted 15,000 shares of Orchestra BioMed HoldingsSEC Form 48 August 2025"Common Stock, par value $0.0001 per share (""Common Stock"")" · traded 7 August 2025 · filed 8 August 2025
- was granted 19,506 shares of Lifecore Biomedical, Inc. \de\SEC Form 417 July 2025Common Stock · traded 15 July 2025 · filed 17 July 2025
- was granted 36,797 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 427 June 2025Stock Option (Right to Buy) · traded 24 June 2025 · filed 27 June 2025
- was granted 12,422 shares of Orchestra BioMed HoldingsSEC Form 427 June 2025"Common Stock, par value $0.0001 per share (""Common Stock"")" · traded 24 June 2025 · filed 27 June 2025
- was granted 5,783 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 410 June 2025Non-Qualified Stock Option (right to buy) · traded 6 June 2025 · filed 10 June 2025
- was granted 1,209 shares of Ligand PharmaceuticalsSEC Form 410 June 2025Common Stock · traded 6 June 2025 · filed 10 June 2025
- was granted 25,000 shares of Anebulo Pharmaceuticals (a derivative holding)SEC Form 47 April 2025Stock Option (right to buy) · traded 4 April 2025 · filed 7 April 2025
- was granted 4,964 shares of Anebulo Pharmaceuticals (a derivative holding)SEC Form 47 April 2025Stock Option (right to buy) · traded 4 April 2025 · filed 7 April 2025
- exercised options over 11,700 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 430 December 2024Stock Option (Right to Buy) · traded 27 December 2024 · filed 30 December 2024
- exercised options over 11,700 shares of Orchestra BioMed HoldingsSEC Form 430 December 2024"Common Stock, par value $0.0001 per share (""Common Stock"")" · traded 27 December 2024 · filed 30 December 2024
- was granted 24,554 shares of Lifecore Biomedical, Inc. \de\SEC Form 421 August 2024Common Stock · traded 19 August 2024 · filed 21 August 2024
- was granted 17,068 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 421 June 2024Stock Option (Right to Buy) · traded 20 June 2024 · filed 21 June 2024
- was granted 5,376 shares of Orchestra BioMed HoldingsSEC Form 421 June 2024"Common Stock, par value $0.0001 per share (""Common Stock"")" · traded 20 June 2024 · filed 21 June 2024
- was granted 5,444 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 418 June 2024Non-Qualified Stock Option (right to buy) · traded 14 June 2024 · filed 18 June 2024
- was granted 1,252 shares of Ligand PharmaceuticalsSEC Form 418 June 2024Common Stock · traded 14 June 2024 · filed 18 June 2024
- was granted 41,667 shares of Anebulo Pharmaceuticals (a derivative holding)SEC Form 417 June 2024Stock Option (right to buy) · traded 13 June 2024 · filed 17 June 2024
- was granted 2,482 shares of Anebulo Pharmaceuticals (a derivative holding)SEC Form 417 June 2024Stock Option (right to buy) · traded 13 June 2024 · filed 17 June 2024
- exercised options over 2,406 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 42 May 2024Non-Qualified Stock Option (right to buy) · traded 30 April 2024 · filed 2 May 2024
- exercised options over 2,406 shares of Ligand PharmaceuticalsSEC Form 42 May 2024Common Stock · traded 30 April 2024 · filed 2 May 2024
- exercised options over 2,893 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 46 March 2024Non-Qualified Stock Option (right to buy) · traded 5 March 2024 · filed 6 March 2024
- exercised options over 2,893 shares of Ligand PharmaceuticalsSEC Form 46 March 2024Common Stock · traded 5 March 2024 · filed 6 March 2024
- was granted 25,000 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 424 July 2023Stock Option (Right to Buy) · traded 20 July 2023 · filed 24 July 2023
- was granted 5,461 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 413 June 2023Non-Qualified Stock Option (right to buy) · traded 9 June 2023 · filed 13 June 2023
- was granted 1,142 shares of Ligand PharmaceuticalsSEC Form 413 June 2023Common Stock · traded 9 June 2023 · filed 13 June 2023
- was granted 23,250 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 419 May 2023Nonstatutory Stock Option (Right to Buy) · traded 26 January 2023 · filed 19 May 2023
- was granted 22,492 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 45 May 2023Right to Receive Earnout Shares · traded 26 January 2023 · filed 5 May 2023
- exercised options over 11,246 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 45 May 2023Right to Receive Earnout Shares · traded 12 April 2023 · filed 5 May 2023
- exercised options over 11,246 shares of Orchestra BioMed HoldingsSEC Form 45 May 2023"Common Stock, par value $0.0001 per share (""Common Stock"")" · traded 12 April 2023 · filed 5 May 2023
- was granted 18,600 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 430 January 2023Nonstatutory Stock Option (Right to Buy) · traded 26 January 2023 · filed 30 January 2023
- was granted 6,975 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 430 January 2023Nonstatutory Stock Option (Right to Buy) · traded 26 January 2023 · filed 30 January 2023
- was granted 23,250 shares of Orchestra BioMed Holdings (a derivative holding)SEC Form 430 January 2023Nonstatutory Stock Option (Right to Buy) · traded 26 January 2023 · filed 30 January 2023
- was granted 51,738 shares of Orchestra BioMed HoldingsSEC Form 430 January 2023"Common Stock, par value $0.0001 per share (""Common Stock"")" · traded 26 January 2023 · filed 30 January 2023
- was granted 4,484 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 427 December 2022Non-Qualified Stock Option (right to buy) · traded 22 December 2022 · filed 27 December 2022
- was granted 30,425 shares of Anebulo Pharmaceuticals (a derivative holding)SEC Form 43 October 2022Stock Option (right to buy) · traded 21 April 2022 · filed 3 October 2022
- was granted 4,340 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 413 June 2022Non-Qualified Stock Option (right to buy) · traded 10 June 2022 · filed 13 June 2022
- was granted 1,004 shares of Ligand PharmaceuticalsSEC Form 413 June 2022Common Stock · traded 10 June 2022 · filed 13 June 2022
- was granted 3,269 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 47 June 2021Non-Qualified Stock Option (right to buy) · traded 4 June 2021 · filed 7 June 2021
- was granted 630 shares of Ligand PharmaceuticalsSEC Form 47 June 2021Common Stock · traded 4 June 2021 · filed 7 June 2021
- was granted 2,468 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 412 June 2020Non-Qualified Stock Option (right to buy) · traded 10 June 2020 · filed 12 June 2020
- was granted 831 shares of Ligand PharmaceuticalsSEC Form 412 June 2020Common Stock · traded 10 June 2020 · filed 12 June 2020
- ▲ bought on the open market 750 shares of Ligand PharmaceuticalsSEC Form 44 September 2019Common Stock · traded 3 September 2019 · filed 4 September 2019
- ▲ bought on the open market 746 shares of Ligand PharmaceuticalsSEC Form 46 August 2019Common Stock · traded 5 August 2019 · filed 6 August 2019
- ▲ bought on the open market 250 shares of Ligand PharmaceuticalsSEC Form 431 July 2019Common Stock · traded 29 July 2019 · filed 31 July 2019
- ▲ bought on the open market 3,000 shares of Ligand PharmaceuticalsSEC Form 431 July 2019Common Stock · traded 30 July 2019 · filed 31 July 2019
- ▲ bought on the open market 754 shares of Ligand PharmaceuticalsSEC Form 431 July 2019Common Stock · traded 31 July 2019 · filed 31 July 2019
- ▲ bought on the open market 302 shares of Merrimack PharmaceuticalsSEC Form 418 July 2019Common Stock · traded 16 July 2019 · filed 18 July 2019
- ▲ bought on the open market 100 shares of Merrimack PharmaceuticalsSEC Form 415 July 2019Common Stock · traded 11 July 2019 · filed 15 July 2019
- ▲ bought on the open market 2,400 shares of Merrimack PharmaceuticalsSEC Form 415 July 2019Common Stock · traded 12 July 2019 · filed 15 July 2019
- ▲ bought on the open market 1,000 shares of Merrimack PharmaceuticalsSEC Form 415 July 2019Common Stock · traded 12 July 2019 · filed 15 July 2019
- ▲ bought on the open market 250 shares of Ligand PharmaceuticalsSEC Form 412 June 2019Common Stock · traded 11 June 2019 · filed 12 June 2019
- was granted 4,071 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 47 June 2019Non-Qualified Stock Option (right to buy) · traded 6 June 2019 · filed 7 June 2019
- was granted 835 shares of Ligand PharmaceuticalsSEC Form 47 June 2019Common Stock · traded 6 June 2019 · filed 7 June 2019
- ▲ bought on the open market 250 shares of Ligand PharmaceuticalsSEC Form 431 May 2019Common Stock · traded 29 May 2019 · filed 31 May 2019
- ▲ bought on the open market 250 shares of Ligand PharmaceuticalsSEC Form 431 May 2019Common Stock · traded 30 May 2019 · filed 31 May 2019
- ▲ bought on the open market 500 shares of Ligand PharmaceuticalsSEC Form 431 May 2019Common Stock · traded 31 May 2019 · filed 31 May 2019
- ▲ bought on the open market 250 shares of Ligand PharmaceuticalsSEC Form 422 May 2019Common Stock · traded 20 May 2019 · filed 22 May 2019
- ▲ bought on the open market 250 shares of Ligand PharmaceuticalsSEC Form 416 May 2019Common Stock · traded 14 May 2019 · filed 16 May 2019
- ▲ bought on the open market 202 shares of Ligand PharmaceuticalsSEC Form 415 March 2019Common Stock · traded 13 March 2019 · filed 15 March 2019
- ▼ sold on the open market 1,080 shares of Ligand PharmaceuticalsSEC Form 417 August 2018Common Stock · traded 16 August 2018 · filed 17 August 2018
- ▼ sold on the open market 26,862 shares of Ligand PharmaceuticalsSEC Form 417 August 2018Common Stock · traded 17 August 2018 · filed 17 August 2018
- was granted 2,474 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 43 July 2018Non-Qualified Stock Option (right to buy) · traded 19 June 2018 · filed 3 July 2018
- was granted 2,474 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 421 June 2018Non-Qualified Stock Option (right to buy) · traded 19 June 2018 · filed 21 June 2018
- was granted 493 shares of Ligand PharmaceuticalsSEC Form 421 June 2018Common Stock · traded 19 June 2018 · filed 21 June 2018
- ▼ sold on the open market 3,500 shares of Ligand PharmaceuticalsSEC Form 49 March 2018Common Stock · traded 8 March 2018 · filed 9 March 2018
- ▼ sold on the open market 4,000 shares of Ligand PharmaceuticalsSEC Form 49 March 2018Common Stock · traded 9 March 2018 · filed 9 March 2018
- gave away 1,000 shares of Ligand PharmaceuticalsSEC Form 427 February 2018Common Stock · traded 26 February 2018 · filed 27 February 2018
- ▼ sold on the open market 3,417 shares of Ligand PharmaceuticalsSEC Form 427 February 2018Common Stock · traded 23 February 2018 · filed 27 February 2018
- ▼ sold on the open market 24,400 shares of Ligand PharmaceuticalsSEC Form 420 November 2017Common Stock · traded 17 November 2017 · filed 20 November 2017
- ▼ sold on the open market 2,000 shares of Ligand PharmaceuticalsSEC Form 425 August 2017Common Stock · traded 23 August 2017 · filed 25 August 2017
- was granted 666 shares of Ligand PharmaceuticalsSEC Form 426 May 2017Common Stock · traded 25 May 2017 · filed 26 May 2017
- was granted 2,456 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 426 May 2017Non-Qualified Stock Option (right to buy) · traded 25 May 2017 · filed 26 May 2017
- ▼ sold on the open market 51,041 shares of Aralez PharmaceuticalsSEC Form 424 May 2017Common Shares, without par value · traded 19 May 2017 · filed 24 May 2017
- ▼ sold on the open market 233,468 shares of Aralez PharmaceuticalsSEC Form 424 May 2017Common Shares, without par value · traded 22 May 2017 · filed 24 May 2017
- ▼ sold on the open market 104,176 shares of Aralez PharmaceuticalsSEC Form 424 May 2017Common Shares, without par value · traded 23 May 2017 · filed 24 May 2017
- ▲ bought on the open market 361 shares of Novelion TherapeuticsSEC Form 417 May 2017Common Shares · traded 15 May 2017 · filed 17 May 2017
- ▼ sold on the open market 22,665 shares of Ligand PharmaceuticalsSEC Form 412 May 2017Common Stock · traded 11 May 2017 · filed 12 May 2017
- ▼ sold on the open market 14,582 shares of Ligand PharmaceuticalsSEC Form 412 May 2017Common Stock · traded 12 May 2017 · filed 12 May 2017
- was granted 7,500 shares of Aralez PharmaceuticalsSEC Form 412 May 2017Common Shares, without par value · traded 11 May 2017 · filed 12 May 2017
- was granted 15,000 shares of Aralez Pharmaceuticals (a derivative holding)SEC Form 412 May 2017Director Stock Option (right to buy) · traded 11 May 2017 · filed 12 May 2017
- ▲ bought on the open market 295,929 shares of Aralez PharmaceuticalsSEC Form 425 April 2017Common Shares, without par value · traded 16 September 2016 · filed 25 April 2017
- ▼ sold on the open market 25,000 shares of Ligand PharmaceuticalsSEC Form 428 February 2017Common Stock · traded 27 February 2017 · filed 28 February 2017
- ▼ sold on the open market 7,000 shares of Ligand PharmaceuticalsSEC Form 428 February 2017Common Stock · traded 28 February 2017 · filed 28 February 2017
- was granted 22,500 shares of Immunomedics (a derivative holding)SEC Form 410 January 2017Stock Options (right to buy) · traded 8 January 2017 · filed 10 January 2017
- was granted 9,600 shares of Novelion Therapeutics (a derivative holding)SEC Form 427 December 2016Stock Option (Right to Buy) · traded 22 December 2016 · filed 27 December 2016
- was granted 1,136,363 shares of Qlt Inc/bcSEC Form 41 December 2016Common Shares, without par value · traded 29 November 2016 · filed 1 December 2016
- was granted 175,979 shares of Qlt Inc/bcSEC Form 41 December 2016Common Shares, without par value · traded 29 November 2016 · filed 1 December 2016
- was granted 31,280 shares of Qlt Inc/bcSEC Form 41 December 2016Common Shares, without par value · traded 29 November 2016 · filed 1 December 2016
- was granted 82,765 shares of Qlt Inc/bcSEC Form 41 December 2016Common Shares, without par value · traded 29 November 2016 · filed 1 December 2016
- ▼ sold on the open market 15,001 shares of Ligand PharmaceuticalsSEC Form 425 November 2016Common Stock · traded 22 November 2016 · filed 25 November 2016
- ▼ sold on the open market 3,478 shares of Ligand PharmaceuticalsSEC Form 425 November 2016Common Stock · traded 25 November 2016 · filed 25 November 2016
- ▼ sold on the open market 1,330 shares of Ligand PharmaceuticalsSEC Form 418 November 2016Common Stock · traded 16 November 2016 · filed 18 November 2016
- ▼ sold on the open market 5,000 shares of Ligand PharmaceuticalsSEC Form 418 November 2016Common Stock · traded 18 November 2016 · filed 18 November 2016
- was granted 100,000 shares of Qlt Inc/bc (a derivative holding)SEC Form 421 June 2016Stock Option (right to buy) · traded 17 June 2016 · filed 21 June 2016
- was granted 12,800 shares of Qlt Inc/bc (a derivative holding)SEC Form 421 June 2016Phantom Stock · traded 17 June 2016 · filed 21 June 2016
- was granted 7,500 shares of Aralez PharmaceuticalsSEC Form 420 June 2016Common Shares, without par value · traded 16 June 2016 · filed 20 June 2016
- was granted 15,000 shares of Aralez Pharmaceuticals (a derivative holding)SEC Form 420 June 2016Employee Stock Option (right to buy) · traded 16 June 2016 · filed 20 June 2016
- was granted 622 shares of Ligand PharmaceuticalsSEC Form 425 May 2016Common Stock · traded 23 May 2016 · filed 25 May 2016
- was granted 2,329 shares of Ligand Pharmaceuticals (a derivative holding)SEC Form 425 May 2016Non-Qualified Stock Option (right to buy) · traded 23 May 2016 · filed 25 May 2016
- ▼ sold on the open market 10,000 shares of Ligand PharmaceuticalsSEC Form 49 May 2016Common Stock · traded 5 May 2016 · filed 9 May 2016
- ▼ sold on the open market 15,000 shares of Ligand PharmaceuticalsSEC Form 49 May 2016Common Stock · traded 6 May 2016 · filed 9 May 2016
- ▼ sold on the open market 5,629 shares of Ligand PharmaceuticalsSEC Form 49 March 2016Common Stock · traded 7 March 2016 · filed 9 March 2016
- ▼ sold on the open market 500 shares of Ligand PharmaceuticalsSEC Form 49 March 2016Common Stock · traded 8 March 2016 · filed 9 March 2016
- ▲ bought on the open market 18,000 shares of Qlt Inc/bcSEC Form 430 December 2015Common Shares · traded 29 December 2015 · filed 30 December 2015
- ▲ bought on the open market 400 shares of Qlt Inc/bcSEC Form 430 December 2015Common Shares · traded 29 December 2015 · filed 30 December 2015
- ▼ sold on the open market 3,000 shares of Ligand PharmaceuticalsSEC Form 413 November 2015Common Stock · traded 11 November 2015 · filed 13 November 2015
- exercised options over 25,000 shares of Qlt Inc/bcSEC Form 41 July 2015Common Shares · traded 30 June 2015 · filed 1 July 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.